A Transgenic Mouse Prostate Cancer Model

Toxicologic Pathology

Volumn 24, Issue 4, 1996, Pages 502-504

  Gingrich, J R ^a   Greenberg, N M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MODEL; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; TRANSGENE; TRANSGENIC MOUSE;

ADENOCARCINOMA; ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TRANSGENES;

ANIMALIA; MUS MUSCULUS;

EID: 0029791591     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262339602400414     Document Type: Article

References (21)

1. Adams JM and Cory S. (1991). Transgenic models of tumor development. Science 254: 1161-1167.
2. Bauer JJ, Sesterhenn IA, Mostofi KF, McLeod DG, Srivastava S., and Moul JW (1995). P53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin. Cancer Res. 1(11): 1295-1300.
3. Brinster RL, Chen HY, Messing A., Van Dyke T., Levine AJ, and Palmiter RD (1984). Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell 37: 367-379.
4. DeCaprio JA, Ludlow JW, Figge J., Shew J.-Y., Huang C.-M., Lee W.-H., Marsilio E., Paucha E., and Livingston DM (1988). SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 17: 275-283.
5. Eastham JA, Stapleton A., Gousse AE, Timme TL, Yang G., Slawin KM, Wheeler TM, Scardino PT, and Thompson TC (1995). Association of p53 mutations with metastatic prostate cancer. Clin. Cancer Res. 1(10): 1111-1118.
6. Greenberg NM, DeMayo F., Finegold MJ, Medina D., Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, and Rosen JM (1995). Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA 92: 3439-3443.
7. Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R., Lebovitz R., Finegold M., Angelopolou R., Dodd JG, Duckworth ML, Rosen JM, and Matusik RJ (1994). The rat probasin gene promoter directs hormonally- and developmentally-regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol. Endocrinol. 8: 230-239.
8. Hall MC, Navone NM, Troncoso P., Pollack A., Zagars GK, Voneschenbach AC, Conti CJ, and Chung L. (1995). Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 45(3): 470-475.
9. Hanahan D. (1985). Heritable formation of pancreatic β-cell tumors in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature (London) 315: 115-122.
10. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, and Srivastava S. (1995). Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol. 154(2, Pt. 1): 414-421.
11. Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, and Ewing CM (1994). Molecular biology of prostate cancer. Semin. Oncol. 21 (5): 514-521.
12. Ittmann MM and Wieczorek R. (1996). Alterations of the retinoblastoma gene in clinically localized, stage b prostate adenocarcinomas. Hum. Pathol. 27(1): 28-34.
13. Konishi N., Hiasa Y., Tsuzuki T., Matsuda H., Tao M., Nakamura M., Naito H., Kitahori Y., Shiraishi T., Yatani R., Shimazaki J., and Lin JC (1996). Detection of rb, p16/cdkn2 and p15(ink4b) gene alterations with immunohistochemical studies in human prostate carcinomas. Int. J. Oncol. 8(1): 107-112.
14. Kubota Y., Shuin T., Uemura H., Fujinami K., Miyamoto H., Torigoe S., Dobashi Y., Kitamura H., Iwasaki Y., Danenberg K., and Danenberg PV (1995). Tumor suppressor gene p53 mutations in human prostate cancer. Prostate 27(1): 18-24.
15. Lane DP and Crawford LV (1979). T-antigen is bound to host proteins in SV-40 transformed cells. Nature (London) 278: 261-263.
16. Linzer DIH and Levine AJ (1979). Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17: 43-52.
17. Maroulakou IG, Anver M., Garrett L., and Green JE (1994). Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc. Natl. Acad. Sci. USA 91: 11236-11240.
18. Palmiter RD and Brinster RL (1985). Transgenic mice. Cell 41: 343-345.
19. Sandgren EP, Quaife CJ, Pinkert CA, Palmiter RD, and Brinster RL (1989). Oncogene-induced liver neoplasia in transgenic mice. Oncogene 4(6): 715-724.
20. Sarkar FH, Sakr W., Li YW, Macoska J., Ball DE, and Crissman JD (1992). Analysis of retinoblastoma (RB) gene deletion in human prostatic carcinomas. Prostate 21(2): 145-152.
21. Yang G., Stapleton A., Wheeler TM, Truong LD, Timme TL, Scardino PT, and Thompson TC (1996). Clustered p53 immunostaining-A novel pattern associated with prostate cancer progression. Clin. Cancer Res. 2(2): 399-401.